Triochem Posts ₹9.48 Lakh Q1FY27 Profit on Other Income

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights

Triochem Products Ltd reported a Q1FY27 net profit of ₹9.48 lakh, reversing a prior-year loss, despite zero operational revenue. The profit stems from other income of ₹16.56 lakh against reduced expenses. The Board cited post-pandemic challenges in relationship-driven sales but highlighted liquidity comfort following the monetization of non-core assets in the previous year.

powered bylight_fuzz_icon
47896172

*this image is generated using AI for illustrative purposes only.

Triochem Products Limited reported a net profit of ₹9.48 lakh for the quarter ended June 30, 2026, marking a turnaround from the net loss of ₹3.06 lakh recorded in the corresponding period of FY25. The company’s total income for the quarter was ₹16.56 lakh, derived entirely from other income, as revenue from operations remained at zero.

Financial Performance

The unaudited standalone financial results, approved by the Board of Directors on August 14, 2026, reveal a significant divergence between operational activity and bottom-line performance. While the company generated no revenue from its core chemical and pharmaceuticals segment, it managed to reduce expenses to ₹4.17 lakh, down from ₹37.34 lakh in Q1FY25. This reduction was primarily driven by lower employee benefit expenses (₹0.75 lakh vs ₹13.52 lakh) and other expenditure (₹3.42 lakh vs ₹22.18 lakh).

Metric: Q1FY27 Q1FY26 Change
Revenue from Operations: ₹0 lakh ₹0 lakh
Other Income: ₹16.56 lakh ₹22.10 lakh -25.1%
Total Income: ₹16.56 lakh ₹22.10 lakh -25.1%
Total Expenses: ₹4.17 lakh ₹37.34 lakh -88.8%
Profit Before Tax: ₹12.39 lakh (₹15.24 lakh) Turnaround
Net Profit: ₹9.48 lakh (₹3.06 lakh) Turnaround

The profit before tax stood at ₹12.39 lakh, with a total tax expense of ₹2.91 lakh comprising current tax of ₹2.63 lakh and deferred tax of ₹0.28 lakh. Earnings per share (EPS) were ₹3.87, compared to a loss of ₹1.25 per share in the previous year’s quarter.

Business Outlook and Asset Monetization

During the board meeting, directors discussed the ongoing impact of the post-COVID-19 pandemic on the business model. The company noted that sectors requiring personal presentation and relationship building have faced a "tremendous hit" with no immediate possibility of revival. Regular customer business is shrinking, with no significant improvement expected in the near term.

To address liquidity and strategic needs, Triochem previously approved the sale of certain immovable properties, plant, machinery, and investment properties in Maharashtra. Shareholder approval via postal ballot was obtained in December 2025. The assets, with a written-down value of ₹56.92 lakh, were sold for a fair market value of approximately ₹1,173.20 lakh (₹672.05 lakh for property, plant & machinery and ₹501.15 lakh for investment properties). This resulted in an exceptional gain of ₹1,116.65 lakh, which was recognized in the previous financial year’s results. The proceeds were received in cash and are proposed to be utilized for funding new business ventures and strategic initiatives.

What the Numbers Show

The current quarter’s profitability is entirely non-operational. With zero revenue from operations, the ₹9.48 lakh net profit is driven by other income exceeding minimal operational costs. This highlights the company’s transition phase, where core business activities have effectively paused while management focuses on asset monetization and potential new ventures. The sharp decline in expenses suggests a lean operational structure maintained during this period of low activity.

Regulatory Compliance

The financial results were reviewed by the Audit Committee and approved by the Board in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kanu Doshi Associates LLP, the statutory auditors, issued an unqualified conclusion on the unaudited quarterly financial results. The company confirmed compliance with applicable securities laws and noted that there were no deviations or variations in public issues during the quarter.

Historical Stock Returns for Triochem Products

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%0.0%0.0%0.0%0.0%0.0%

What specific new business ventures or strategic initiatives does Triochem plan to launch using the ₹1,173.20 lakh proceeds from its recent asset sales?

Given the management's assessment that core sectors requiring personal presentation face no immediate revival, what is the timeline for Triochem to exit or restructure its traditional chemical and pharmaceuticals operations?

How will the company's investment strategy evolve now that it has transitioned from a loss-making operational entity to a cash-rich holding structure with minimal ongoing expenses?

Triochem Products opens e-voting for 54th AGM on Aug 22

scanx
Reviewed by
Riya DScanX News Team
Key Highlights

Triochem Products Limited has scheduled its 54th Annual General Meeting for August 22, 2026, with remote e-voting available from August 19 to 21 for shareholders on record as of August 14. The meeting will address the adoption of FY26 financials, which showed a ₹797.07 lakh net profit driven by exceptional gains from asset sales, and the re-appointment of director Shyam Sundar Sharma.

powered bylight_fuzz_icon
46960991

*this image is generated using AI for illustrative purposes only.

Triochem Products Limited will hold its 54th Annual General Meeting (AGM) on Saturday, August 22, 2026, at its registered office in Mumbai. The meeting aims to approve financial results for FY26 and re-appoint director Shyam Sundar Sharma. Remote e-voting is open to shareholders holding shares as of the August 14, 2026, cut-off date, with voting accessible from August 19 to August 21 via Central Depository Services Limited (CDSL). This procedural update follows the company’s recent disclosure of a ₹797.07 lakh net profit for FY26, driven by asset sales rather than operational revenue.

The Board of Directors convened the AGM to transact ordinary and special business, including the adoption of financial statements and the re-appointment of Mr. Shyam Sundar Sharma as a Non-Executive, Non-Independent Director. Mr. Sharma, aged 79, retires by rotation but remains eligible for re-appointment under Regulation 17(1A) of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. A special resolution is required for directors over the age of 75. Mrs. Ragini Chokshi of M/s. Ragini Chokshi & Co. has been appointed as the scrutinizer to oversee the e-voting process.

E-Voting and Book Closure Details

Shareholders must act within specific windows to exercise their voting rights. The register of members and share transfer books will remain closed from August 16, 2026, to August 22, 2026. The remote e-voting period begins at 9:00 AM IST on Wednesday, August 19, 2026, and ends at 5:00 PM IST on Friday, August 21, 2026. Only members whose names appear in the register of members or depository records as of the cut-off date, August 14, 2026, are entitled to vote.

Key Date Event Details
August 14, 2026 Cut-off Date Record date for determining voting eligibility
August 16–22, 2026 Book Closure Register of members closed for AGM purposes
August 19–21, 2026 E-Voting Window Remote voting open via CDSL platform
August 22, 2026 AGM Date Physical meeting at 3:00 PM in Mumbai

Members who have not registered or updated their email addresses with their Depository Participant or Registrar & Transfer Agent are requested to do so to receive electronic copies of the notice and annual report. Technical support for e-voting login issues is available through CDSL and NSDL helpdesks. Members who cast their votes electronically before the meeting may attend the AGM but cannot vote again.

Financial Context and Operational Status

The AGM agenda includes the approval of FY26 financials, which reported a net profit of ₹797.07 lakh, reversing a net loss of ₹40.01 lakh in FY25. This turnaround was entirely due to an exceptional gain of ₹1,116.65 lakh from the sale of immovable properties, plant, and machinery. Operating revenue remained nil, as the company had no manufacturing activities during the period. Other income declined to ₹86.45 lakh from ₹105.01 lakh in FY25, while EBITDA widened to a loss of ₹60.19 lakh.

The asset sales were executed between January 19, 2026, and February 5, 2026, following shareholder approval via postal ballot on December 13, 2025. The transaction was classified as a Material Related Party Transaction under Section 188 of the Companies Act, 2013, and Regulation 23 of the SEBI LODR Regulations, 2015. An independent valuer certified the fair market value at approximately ₹672.05 lakh for property, plant, and machinery, and ₹501.15 lakh for investment properties. The assets sold had an aggregate written-down value of ₹56.92 lakh.

What the Numbers Show

The financial results highlight a complete disconnect between operational performance and profitability. With zero revenue from operations and a widening EBITDA loss, the company’s core business activities are dormant. The reported net profit is attributable solely to the one-time monetization of non-core assets. While the balance sheet has been strengthened with cash proceeds—totaling approximately ₹1,961.73 lakh as of March 31, 2026—there is no underlying operational cash flow to sustain earnings. Investors should note that management intends to use these proceeds for new business ventures, but no new revenue streams have been established yet. Statutory auditors Kanu Doshi Associates LLP issued an unqualified opinion on the financial statements.

Historical Stock Returns for Triochem Products

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%0.0%0.0%0.0%0.0%0.0%

What specific new business ventures has Triochem Products outlined for deployment of the ₹1,961.73 lakh cash proceeds from asset sales?

How will the company address the widening EBITDA loss and nil operating revenue in FY27 without active manufacturing activities?

Are there any pending legal or regulatory liabilities associated with the dormant operational assets that could impact future cash flows?

More News on Triochem Products

1 Year Returns:0.00%